WallStreetZenWallStreetZen

NASDAQ: IKNA
Ikena Oncology Inc Stock Forecast, Predictions & Price Target

Analyst price target for IKNA

Based on 2 analysts offering 12 month price targets for Ikena Oncology Inc.
Min Forecast
$2.00+16.96%
Avg Forecast
$3.00+75.44%
Max Forecast
$4.00+133.92%

Should I buy or sell IKNA stock?

Based on 2 analysts offering ratings for Ikena Oncology Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IKNA stock forecasts and price targets.

IKNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-29
lockedlocked$00.00+00.00%2024-05-29

1 of 1

Forecast return on equity

Is IKNA forecast to generate an efficient return?
Company
-24.23%
Industry
73.55%
Market
80.58%
IKNA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IKNA forecast to generate an efficient return on assets?
Company
-21.79%
Industry
31.45%
IKNA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IKNA earnings per share forecast

What is IKNA's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.22
Avg 2 year Forecast
-$1.02
Avg 3 year Forecast
-$0.83

IKNA revenue forecast

What is IKNA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$14.0M+263.83%
Avg 2 year Forecast
$20.0M+419.75%
Avg 3 year Forecast
$40.0M+939.5%
IKNA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IKNA revenue growth forecast

How is IKNA forecast to perform vs Biotechnology companies and vs the US market?
Company
113.91%
Industry
37.21%
Market
10.62%
IKNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IKNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IKNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IKNA$1.71$3.00+75.44%Buy
TIL$12.72$20.33+59.85%Buy
MIST$1.56$15.00+861.54%Strong Buy
TLSA$0.81N/AN/A
CASI$6.23$6.00-3.69%Buy

Ikena Oncology Stock Forecast FAQ

Is Ikena Oncology Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: IKNA) stock is to Buy IKNA stock.

Out of 2 analysts, 0 (0%) are recommending IKNA as a Strong Buy, 1 (50%) are recommending IKNA as a Buy, 1 (50%) are recommending IKNA as a Hold, 0 (0%) are recommending IKNA as a Sell, and 0 (0%) are recommending IKNA as a Strong Sell.

If you're new to stock investing, here's how to buy Ikena Oncology stock.

What is IKNA's earnings growth forecast for 2024-2026?

(NASDAQ: IKNA) Ikena Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.78%.

Ikena Oncology's earnings in 2024 is -$70,093,000.On average, 4 Wall Street analysts forecast IKNA's earnings for 2024 to be -$58,874,895, with the lowest IKNA earnings forecast at -$74,800,072, and the highest IKNA earnings forecast at -$42,949,719. On average, 4 Wall Street analysts forecast IKNA's earnings for 2025 to be -$49,343,918, with the lowest IKNA earnings forecast at -$70,939,423, and the highest IKNA earnings forecast at -$29,437,448.

In 2026, IKNA is forecast to generate -$40,054,232 in earnings, with the lowest earnings forecast at -$52,118,760 and the highest earnings forecast at -$24,611,637.

What is IKNA's revenue growth forecast for 2024-2026?

(NASDAQ: IKNA) Ikena Oncology's forecast annual revenue growth rate of 113.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Ikena Oncology's revenue in 2024 is $3,848,000.On average, 1 Wall Street analysts forecast IKNA's revenue for 2024 to be $675,613,554, with the lowest IKNA revenue forecast at $675,613,554, and the highest IKNA revenue forecast at $675,613,554. On average, 1 Wall Street analysts forecast IKNA's revenue for 2025 to be $965,162,220, with the lowest IKNA revenue forecast at $965,162,220, and the highest IKNA revenue forecast at $965,162,220.

In 2026, IKNA is forecast to generate $1,930,324,440 in revenue, with the lowest revenue forecast at $1,930,324,440 and the highest revenue forecast at $1,930,324,440.

What is IKNA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: IKNA) forecast ROA is -21.79%, which is lower than the forecast US Biotechnology industry average of 31.45%.

What is IKNA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year IKNA price target, the average IKNA price target is $3.00, with the highest IKNA stock price forecast at $4.00 and the lowest IKNA stock price forecast at $2.00.

On average, Wall Street analysts predict that Ikena Oncology's share price could reach $3.00 by May 29, 2025. The average Ikena Oncology stock price prediction forecasts a potential upside of 75.44% from the current IKNA share price of $1.71.

What is IKNA's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: IKNA) Ikena Oncology's current Earnings Per Share (EPS) is -$1.57. On average, analysts forecast that IKNA's EPS will be -$1.22 for 2024, with the lowest EPS forecast at -$1.55, and the highest EPS forecast at -$0.89. On average, analysts forecast that IKNA's EPS will be -$1.02 for 2025, with the lowest EPS forecast at -$1.47, and the highest EPS forecast at -$0.61. In 2026, IKNA's EPS is forecast to hit -$0.83 (min: -$1.08, max: -$0.51).

What is IKNA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: IKNA) forecast ROE is -24.23%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.